Eucker J, Emde A, Possinger K
Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie, Charité, Universitätsmedizin Berlin, Berlin.
Internist (Berl). 2006 Dec;47(12):1223-4, 1226-8. doi: 10.1007/s00108-006-1728-2.
Breast cancer, as one of the most frequent tumor entities, is the object of intensive research activity. Clinical research over the last few years has resulted in an increasing differentiation in treatment strategies in the adjuvant setting as well as in metastatic breast cancer. Treatment decision is guided by different risk groups, and relevant changes in clinical practice have arisen in hormonal treatment as well as in chemotherapy. Furthermore, new agents have shown clinical activity, in particular trastuzumab has emerged as standard treatment in HER2 positive breast cancer. It was even licensed in 2006 for adjuvant treatment.
乳腺癌作为最常见的肿瘤类型之一，是深入研究的对象。过去几年的临床研究使得辅助治疗以及转移性乳腺癌的治疗策略越来越分化。治疗决策由不同风险组指导，激素治疗和化疗在临床实践中都出现了相关变化。此外，新药物已显示出临床活性，特别是曲妥珠单抗已成为HER2阳性乳腺癌的标准治疗方法。它甚至在2006年被批准用于辅助治疗。
